01—Abstract
Summary
Summary of the 10-K filed February 24, 2012. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2011 10-K filing highlights a year of revenue growth driven by key products like Cymbalta and insulin, alongside a notable increase in its Animal Health segment.
However, this growth was offset by decreased net income, primarily due to the impact of U.S. healthcare reform, increased operating expenses, and charges related to restructuring and collaborations. The company is facing significant patent expirations for major products like Zyprexa and Cymbalta, which are expected to materially impact future revenues. Lilly is actively managing these challenges by investing heavily in its late-stage pipeline, exploring strategic collaborations, and focusing on emerging markets and its animal health business to drive future growth.
The filing also details ongoing legal and regulatory matters, including patent litigation and investigations into marketing practices, which represent potential risks. The company's financial condition remains solid with substantial cash reserves and manageable debt, although it is largely self-insured for product liability claims. Investors should closely monitor the impact of patent expirations, the success of new product development, and the evolving regulatory landscape.
02—Key points
Key Highlights
- Revenue increased by 5% to $24.29 billion in 2011, driven by Cymbalta, insulin products, animal health, Alimta, Effient, and Cialis.
- Net income decreased by 14% to $4.35 billion, or $3.90 per share, due to increased operating expenses and specific charges, including $408.8 million related to U.S. healthcare reform.
- Zyprexa revenue declined by 8% due to patent exclusivity loss in October 2011, with an expected further decline of over $3 billion in 2012.
- The company reported robust growth in its Animal Health segment, with sales increasing by 21% to $1.68 billion.
- R&D expenses increased by 3% to $5.02 billion, reflecting continued investment in a pipeline of approximately 65 potential new drugs.
- Key patent expirations are looming for major products such as Cymbalta (2013) and Humalog (2013), posing a significant risk to future revenue.
- The company is actively involved in patent litigation concerning Alimta and Strattera, with potential material impacts on future results.
- Eli Lilly reported a strong financial position with $6.90 billion in cash, cash equivalents, and short-term investments at year-end 2011.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 24, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $24.29B$23.08B | +5.2% |
| Cost of Revenue | $5.07B$4.37B | +16.1% |
| Gross Profit | $19.22B$18.71B | +2.7% |
| R&D Expenses | $5.02B$4.88B | +2.8% |
| SG&A Expenses | $7.88B$7.05B | +11.7% |
| Interest Expense | $186.00M$185.50M | +0.3% |
| Net Income | $4.35B$5.07B | −14.2% |
| EPS (Basic) | $3.90$4.58 | −14.8% |
| EPS (Diluted) | $3.90$4.58 | −14.8% |
| Shares Outstanding (Basic) | 1.11B1.11B | +0.7% |
| Shares Outstanding (Diluted) | 1.11B1.11B | +0.7% |
05—Questions
Frequently Asked Questions
What are the key products driving Eli Lilly's revenue in 2011?
In 2011, Eli Lilly's revenue was primarily driven by the collective growth of Cymbalta, its insulin products (Humalog and Humulin), animal health products, Alimta, Effient, and Cialis. These products showed strong performance, contributing to overall revenue growth.
What significant risks does Eli Lilly face regarding its product portfolio?
The most significant risk highlighted is the impending loss of patent exclusivity for several major products. Zyprexa has already lost exclusivity in the U.S. and Europe, with expected significant revenue declines. Cymbalta and Humalog are set to lose U.S. patent protection in 2013, and Evista in 2014. The loss of exclusivity typically leads to a rapid and severe decline in sales due to generic competition.
How is Eli Lilly addressing the challenges of patent expirations and investing in future growth?
Eli Lilly is heavily investing in its research and development pipeline, with approximately 65 drug candidates in human testing. The company is also pursuing strategic collaborations, such as the diabetes collaboration with Boehringer Ingelheim, and is focusing on growing its Animal Health business (Elanco) and expanding in emerging markets and Japan. These efforts are aimed at offsetting the impact of patent expirations and driving future revenue streams.
What is the financial health of Eli Lilly as presented in the 2011 10-K?
Eli Lilly maintained a solid financial position in 2011, with cash, cash equivalents, and short-term investments totaling $6.90 billion. The company generated strong operating cash flow and had total debt of $6.99 billion, with a stable outlook from credit rating agencies. Dividends have been paid consistently, indicating financial stability, though the company is largely self-insured for product liability claims.
06—Continue